PIKFYVE and cancer: Importantly, two PIKfyve inhibitors, apilimod and ESK981, have passed phase 1 clinical trials (NCT02594384 and NCT00875264)33,34, highlighting the rapid translational potential of targeting PIKfyve to disrupt autophagy and lysosomal processes in cancers.